Mission and Goals

Timothy Chan

Timothy A. Chan, MD, PhD, PaineWebber Chair in Cancer Genetics; Director, Immunogenomics and Precision Oncology Platform; Member, Human Oncology & Pathogenesis Program; Vice Chair, Department of Radiation Oncology; Director, Translational Oncology Division

Letter from the Director

The physicians and scientists on the IPOP team are dedicated to elucidating the mechanisms underlying immunotherapy efficacy. We seek to identify new immunotherapy targets and to characterize the factors responsible for why certain patients respond, or do not respond, to immune checkpoint inhibitors. Through the use of state-of-the-art immunogenomics, our unique partnerships with Memorial Sloan Kettering scientists and industry leaders have led to many novel discoveries in the areas of tumor mutational burden, neoantigens, and the impact of germline factors on immunotherapy response. 

Timothy A. Chan

Director, Immunogenomics and Precision Oncology Platform

IPOP is a state-of-the-art program dedicated to translational immuno-oncology research, discovery, and collaboration. Our mission is to partner with MSK investigators and industry. IPOP emphasizes large-scale immunogenomics capabilities in partnership with scientists and companies running clinical trials to foster immuno-oncology discovery and drug development. The specific goals of the platform are:

  • engaging in flagship projects with investigators from MSK and other New York-area institutions
  • facilitating more industry contracts and collaborations and enhancing capabilities
  • facilitating more collaborative work on national clinical trials
  • enhancing experimental and analytical capabilities for immunogenomics and large-scale, data-rich immunology studies
  • driving MSK’s intellectual property engine in immuno-oncology
  • developing immuno-oncology–driven diagnostics in partnership with clinical (CLIA-certified) labs at MSK
  • establishing an experimental and analytical engine to tackle the complexity of immunogenomics:
    • cBIO Portal for Immunotherapy: a searchable, minable portal for major genomic, transcriptomic, and high-dimensional immunologic datasets for patients from all over the world treated with immuno-oncology therapeutics, facilitating analysis of features relevant to immuno-oncology, with application-driven access for the research and clinical trials community
    • high-throughput cancer antigen screening platform
    • open-source T cell receptor repertoire sequencing @ MSK: high-throughput processing with Integrated Genomics Operation; analysis portal and end-user data availability
    • flagship precision immuno-oncology projects: industry contracts for innovative clinical trials; precision immunotherapy for kidney cancer and head and neck tumors